Insmed, Inc. (NASDAQ:INSM) Given Average Recommendation of "Buy" by Brokerages

Insmed, Inc. (NASDAQ:INSM - Get Free Report) has been given a consensus rating of "Buy" by the seventeen analysts that are presently covering the company, MarketBeat Ratings reports. Seventeen investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued a report on the stock in the last year is $106.80.

Several research analysts recently weighed in on the stock. Mizuho boosted their price objective on shares of Insmed from $96.00 to $110.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Jefferies Financial Group restated a "buy" rating on shares of Insmed in a research report on Tuesday, June 10th. Leerink Partners raised their price target on Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a report on Tuesday, June 10th. Bank of America boosted their price target on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Finally, Royal Bank Of Canada boosted their target price on Insmed from $99.00 to $106.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th.

Insider Buying and Selling at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 9,925 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $65.47, for a total value of $649,789.75. Following the completion of the transaction, the insider directly owned 86,596 shares in the company, valued at $5,669,440.12. This trade represents a 10.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis sold 129,805 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the completion of the sale, the chief executive officer owned 233,924 shares of the company's stock, valued at approximately $23,483,630.36. This represents a 35.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 488,752 shares of company stock valued at $43,199,826 in the last three months. 3.00% of the stock is currently owned by insiders.

Institutional Trading of Insmed

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Insmed by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock valued at $1,393,675,000 after purchasing an additional 49,149 shares during the period. Darwin Global Management Ltd. raised its stake in Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after purchasing an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Insmed by 1.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock valued at $985,938,000 after purchasing an additional 219,131 shares during the period. Capital International Investors grew its position in shares of Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after purchasing an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Insmed by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after purchasing an additional 273,759 shares during the period.

Insmed Price Performance

Shares of Insmed stock traded up $0.26 during mid-day trading on Tuesday, reaching $98.50. 1,762,381 shares of the stock were exchanged, compared to its average volume of 2,307,570. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. The company has a market cap of $18.69 billion, a price-to-earnings ratio of -16.55 and a beta of 0.90. The firm has a 50-day simple moving average of $80.87 and a 200 day simple moving average of $76.42. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $106.83.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.06) earnings per share. On average, sell-side analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.